HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

25 مايو 2023 19:00:54 بحسب Nasdaq GlobeNewswire

HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting

25 مايو 2023 18:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces Board of Directors and Board Committee Membership

12 مايو 2023 04:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees 

10 مايو 2023 04:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer

17 أبريل 2023 20:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023

11 أبريل 2023 20:00:00 بحسب Nasdaq GlobeNewswire

Intended Retirement of Independent Non-executive Director

11 أبريل 2023 04:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations

04 أبريل 2023 05:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

30 مارس 2023 20:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China

14 مارس 2023 09:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Confirms No Assets Held at Silicon Valley Bank

12 مارس 2023 20:07:31 بحسب Nasdaq GlobeNewswire

HUTCHMED Reports 2022 Full Year Results and Provides Business Updates

28 فبراير 2023 03:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED to Announce 2022 Final Results

31 يناير 2023 03:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China

23 يناير 2023 03:00:55 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China

18 يناير 2023 09:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China

03 يناير 2023 03:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer

19 ديسمبر 2022 05:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals

14 نوفمبر 2022 19:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China

13 نوفمبر 2022 19:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

27 أكتوبر 2022 07:30:00 بحسب Nasdaq GlobeNewswire